Cargando…

Combination Effects of Docetaxel and Doxorubicin in Hormone-Refractory Prostate Cancer Cells

Combination effects of docetaxel (DOC) and doxorubicin (DOX) were investigated in prostate cancer cells (PC3 and DU145). Combination indices (CIs) were determined using the unified theory in various concentrations and mixing ratios (synergy: CI < 0.9, additivity: 0.9 < CI < 1.1, and antagon...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tsakalozou, Eleftheria, Eckman, Allison M., Bae, Younsoo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3395329/ https://www.ncbi.nlm.nih.gov/pubmed/22811914 http://dx.doi.org/10.1155/2012/832059

Ejemplares similares

Docetaxel treatment in the elderly patient with hormone refractory prostate cancer
por: Sinibaldi, Victoria J
Publicado: (2007)

Safety and Efficacy of Cabazitaxel in the Docetaxel-Treated Patients with Hormone-Refractory Prostate Cancer
por: Calcagno, Fabien, et al.
Publicado: (2012)

A systematic review of the effectiveness of docetaxel and mitoxantrone for the treatment of metastatic hormone-refractory prostate cancer
por: Collins, R, et al.
Publicado: (2006)

Docetaxel and Doxorubicin Codelivery by Nanocarriers for Synergistic Treatment of Prostate Cancer
por: Li, Ke, et al.
Publicado: (2019)

Docetaxel induces apoptosis in hormone refractory prostate carcinomas during multiple treatment cycles
por: Kramer, G, et al.
Publicado: (2006)

Docetaxel Chemotherapy of Korean Patients with Hormone-refractory Prostate Cancer : Comparative Analysis between 1st-line and 2nd-line Docetaxel
por: Joung, Jae Young, et al.
Publicado: (2008)

Effectiveness of Docetaxel for Metastatic Hormone-sensitive Prostate Cancer in Clinical Practice
por: Lendorf, Maria Elisabeth, et al.
Publicado: (2021)

Phase I study of BIBF 1120 with docetaxel and prednisone in metastatic chemo-naive hormone-refractory prostate cancer patients
por: Bousquet, G, et al.
Publicado: (2011)

Cabazitaxel versus docetaxel for treatment of metastatic castrate refractory prostate cancer
por: James, Nicholas D., et al.
Publicado: (2022)

Weekly administration of docetaxel in combination with estramustine and celecoxib in patients with advanced hormone-refractory prostate cancer: final results from a phase II study
por: Carles, J, et al.
Publicado: (2007)

Comparison of Doxorubicin Plus Docetaxel Neoadjuvant Chemotherapy with Doxorubicin Plus Vinorelbine in Primary Breast Cancer
por: Gwak, Geumhee, et al.
Publicado: (2011)

Combinational Treatment of Doxorubicin With Neoadjuvant Docetaxel for Different Subtypes of Patients With Breast Cancer
por: Wang, Ling-Cheng, et al.
Publicado: (2020)

Phase II study of sequential chemotherapy with docetaxel–estramustine followed by mitoxantrone–prednisone in patients with advanced hormone-refractory prostate cancer
por: Galli, L, et al.
Publicado: (2007)

Inhibitory effect of roburic acid in combination with docetaxel on human prostate cancer cells
por: Wang, Xiao, et al.
Publicado: (2022)

Pathogenesis of prostate cancer and hormone refractory prostate cancer
por: Girling, J. S., et al.
Publicado: (2007)

Docetaxel Treatment for Metastatic Hormone-sensitive Prostate Cancer in Daily Practice
por: de Groot, Ietsen, et al.
Publicado: (2021)

The Effects and Mechanism of YK-4-279 in Combination with Docetaxel on Prostate Cancer
por: Yu, Lin, et al.
Publicado: (2017)

Feasibility of metronomic chemotherapy with tegafur-uracil, cisplatin, and dexamethasone for docetaxel-refractory prostate cancer
por: Kubota, Hiroki, et al.
Publicado: (2017)

Therapeutic Options in Docetaxel-Refractory Metastatic Castration-Resistant Prostate Cancer: A Cost-Effectiveness Analysis
por: Zhong, Lixian, et al.
Publicado: (2013)

Docetaxel, abiraterone, enzalutamide, apalutamide in patients with metastatic hormone-sensitive prostate cancer
por: Talwar, Harkirat Singh
Publicado: (2021)

Outcomes of Older Men Receiving Docetaxel for Metastatic Hormone-Sensitive Prostate Cancer
por: Lage, Daniel E., et al.
Publicado: (2021)

Leptomeningeal Metastases in Hormone Refractory Prostate Cancer
por: Ng, Jessica Y, et al.
Publicado: (2018)

Radioenhancement with the Combination of Docetaxel and Ultrasound Microbubbles: In Vivo Prostate Cancer
por: Almasri, Firas, et al.
Publicado: (2023)

The Combination of Omega-3 Stearidonic Acid and Docetaxel Enhances Cell Death over Docetaxel Alone in Human Prostate Cancer Cells
por: Mansour, Mahmoud, et al.
Publicado: (2018)

The Effects of Matrine in Combination with Docetaxel on Castration-Resistant (Androgen-Independent) Prostate Cancer
por: Li, Qi, et al.
Publicado: (2019)

Synergistic effects and mechanisms of impressic acid or acankoreanogein in combination with docetaxel on prostate cancer
por: Jiang, Sen, et al.
Publicado: (2018)

Combination Modality Using Quercetin to Enhance the Efficacy of Docetaxel in Prostate Cancer Cells
por: Sharma, Satish, et al.
Publicado: (2023)

Combination of Kaempferol and Docetaxel Induces Autophagy in Prostate Cancer Cells In Vitro and In Vivo
por: Zhou, Qian, et al.
Publicado: (2023)

Physiologically‐based pharmacokinetic modeling to support bioequivalence and approval of generic products: A case for diclofenac sodium topical gel, 1%
por: Tsakalozou, Eleftheria, et al.
Publicado: (2021)

Liver Metastases in Prostate Carcinoma Represent a Relatively Aggressive Subtype Refractory to Hormonal Therapy and Short-Duration Response to Docetaxel Monotherapy
por: Singh, Arsh, et al.
Publicado: (2015)

Combination of pegylated liposomal doxorubicin and docetaxel as neoadjuvant therapy for breast cancer with axillary lymph node metastasis
por: Wang, Li, et al.
Publicado: (2020)

AB084. Docetaxel therapy for hormone-sensitive prostate cancer—single center result
por: Shao, Qiang, et al.
Publicado: (2015)

Combination of gemcitabine and docetaxel: a regimen overestimated in refractory metastatic osteosarcoma?
por: Xu, Jie, et al.
Publicado: (2018)

The chemomodulatory effects of glufosfamide on docetaxel cytotoxicity in prostate cancer cells
por: Attia, Reem T., et al.
Publicado: (2016)

Novel formulations of docetaxel, paclitaxel and doxorubicin in the management of metastatic breast cancer
por: Rajappa, Senthil, et al.
Publicado: (2018)

Docetaxel with or without estramustine for estramustine refractory castration-resistant prostate cancer: a single institution experience
por: Nakano, Kazuhiko, et al.
Publicado: (2012)

Satraplatin in the treatment of hormone-refractory metastatic prostate cancer
por: Armstrong, Andrew J, et al.
Publicado: (2007)

Update in palliative management of hormone refractory cancer of prostate
por: Singh, Pratipal, et al.
Publicado: (2007)

Efficacy and Safety of Androgen-Deprivation Therapy Combined with Docetaxel Plus Prednisone in High-Burden Metastatic Hormone-Sensitive Prostate Cancer
por: Hu, Linjun, et al.
Publicado: (2020)

S-1 combined with docetaxel following doxorubicin plus cyclophosphamide as neoadjuvant therapy in breast cancer: phase II trial
por: Moon, Yong Wha, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_vpc5i8uout85q6nbraokra68p5